Companies like Stripe are avoiding IPOs because the private markets now solve the two main historical drivers: access to capital and employee liquidity. With annual secondary tenders and vast private funding available, the traditional benefits of going public are no longer compelling for many late-stage startups.

A decade ago, 88% of a tech company's value was created post-IPO. For recent IPOs, 55% of the market cap creation happened while the company was still private, fundamentally changing where investors capture growth.

The traditional IPO exit is being replaced by a perpetual secondary market for elite private companies. This new paradigm provides liquidity for investors and employees without the high costs and regulatory burdens of going public. This shift fundamentally alters the venture capital lifecycle, enabling longer private holding periods.

In the 1980s, companies like Apple went public early as a fundraising necessity, allowing public investors to capture most of the growth. Today, robust private markets mean companies stay private longer, making IPOs primarily a liquidity event for insiders and VCs, with less upside left for the public.

In the current market, companies prioritize liquidity and public market access over protecting previous private valuations. A lower IPO price is no longer seen as a failure but as a necessary market correction to move forward and ensure survival.

For high-growth companies, reaching a $100M ARR milestone no longer automatically triggers IPO plans. With abundant private capital, many founders now see going public as an unnecessary burden, preferring to avoid SEC reporting and gain liquidity through private growth rounds.

The abundance of private capital means the most successful companies no longer need to go public for growth funding. This disrupts the traditional VC model, where IPOs are a primary exit path, forcing firms to re-evaluate how and when they achieve liquidity for their limited partners, even for their best assets.

Unlike in tech where an IPO is often a liquidity event for early investors, a biotech IPO is an "entrance." It functions as a financing round to bring in public market capital needed for expensive late-stage trials. The true exit for investors is typically a future acquisition.

Contrary to popular belief, an IPO should not be viewed as a liquidity event. Instead, its primary value is in marketing and branding. It signals to the market, customers, and potential employees that the company is stable and "here to stay." The actual liquidity is often constrained by lockups and regulations.